Effects of pentoxifylline on amikacin-induced nephrotoxicity in rats

Renal Failure

Volumn 31, Issue 2, 2009, Pages 134-139

  Ozer, Mehmet Kaya ^a   Asci, Halil ^a   Oncu, Meral ^a   Yesilot, Sukriye ^a   Savran, Mehtap ^a   Bayram, Dilek ^a   Cicek, Ekrem ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Amikacin; Pentoxifylline; Rat; Renal injury

Indexed keywords

AMIKACIN; CREATININE; MALONALDEHYDE; PENTOXIFYLLINE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE MODEL; DRUG EFFECT; HISTOPATHOLOGY; KIDNEY PARENCHYMA; MALE; MICROSCOPY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; UREA NITROGEN BLOOD LEVEL;

AMIKACIN; ANIMALS; ANTI-BACTERIAL AGENTS; BLOOD UREA NITROGEN; CREATININE; FREE RADICAL SCAVENGERS; KIDNEY; KIDNEY DISEASES; MALE; MALONDIALDEHYDE; PENTOXIFYLLINE; RATS; RATS, WISTAR;

EID: 61649121552     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220802595492     Document Type: Article

References (47)

1. Begg EJ, Barclay ML. Aminoglycosides 50 years on. Br J Clin Pharmacol. 1995;39:597-603.
2. Kaynar K, Gul S, Ersoz S, Ozdemir F, Ulusoy H, Ulusoy S. Amikacin-induced nephropathy: Is there any protective way? Ren Fail. 2007;29(1):23-27.
3. Parlakpinar H, Ozer MK, Ucar M, Gaffaroglu M, Vardi N, Koc M, Acet A. Protective effects of caffeic acid phenethyl ester (CAPE) on amikacin-induced nephrotoxicity in rats. Cell Biochem Funct. 2006 Jul-Aug;24(4):363-367.
4. Horvath B, Marton Z, Halmosi R, Alexy T, Szapary L, Vekasi J, Biro Z, Habon T, Kesmarky G, Toth K. In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine. Clin. Neuropharmacol. 2002;25(1):37-42.
5. Bhat VB, Madyastha KM. Antioxidant and radical scavenging properties of 8-oxo derivatives of xanthine drugs pentoxifylline and lisofylline. Biochem. Biophys. Res. Commun. 2001;288(5):1212-1217.
6. Freitas JP, Filipe P, Guerra-Rodrigo F. Potential antioxidative effects of pentoxifylline. CR Seances Soc. Biol. Fil. 1995;189(3):401-405.
7. Freitas JP, Filipe PM. Pentoxifylline: A hydroxyl radical scavenger. Biol. Trace Elem. Res. 1995;47(1-3):307-311.
8. de Campos T, Deree J, Martins JO, Loomis WH, Shenvi E, Putnam JG, Coimbra R. Pentoxifylline attenuates pulmonary inflammation and neutrophil activation in experimental acute pancreatitis. Pancreas. 2008 Jul;37(1):42-49.
9. Wahhab MA, Nada SA, Arbid MS. Ochratoxicosis: Prevention of developmental toxicity by L-methionine in rats. J Applied Toxicol. 1999;19:7-12.
10. Humes HD. Aminoglycoside nephrotoxicity. Kidney Int. 1988;33:900-911.
11. Nagai J, Tanaka H, Nakanishi N, Murakami T, Takano M. Role of megalin in renal handling of aminoglycosides. Am J Physiol Renal Physiol. 2001;28:337-344.
12. Krysztopik RJ, Matheson PJ, Spain DA, et al. Lazaroid and pentoxifylline suppress sepsis-induced increases in renal vascular resistance via altered arachidonic acid metabolism. J Surg Res. 2000;93:75-81.
13. Ambrus JL, Halpern J, Mahafzah M, et al. Platelet aggregation in septic shock: Effects of pentoxifylline. J Med. 1990;21:121-128.
14. Fink MP. Whither pentoxifylline? Crit Care Med. 1999;27:19-20.
15. Ward A, Clissold SP. Pentoxifylline: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987;34:50-97.
16. Mandell GL. ARDS, neutrophils, and pentoxifylline. Am Rev Respir Dis. 1988;138:1103-1105.
17. Berens KL, Langston JD, Wasan KM, et al. Influence of pentoxifylline and related analogues in endotoxemic renal failure. Circ Shock. 1991;34:344-348.
18. Kim YK, Yoo JH, Woo JS, et al. Effect of pentoxifylline on ischemic acute renal failure in rabbits. Ren Fail. 2001;23:757-772.
19. Kim YK, Choi TR, Kwon CH, et al. Beneficial effect of pentoxifylline on cisplatin-induced acute renal failure in rabbits. Ren Fail. 2003;25:909-922.
20. Savic V, Vlahovic P, Djordjevic V, et al. Nephroprotective effects of pentoxifylline in experimental myoglobinuric acute renal failure. Pathol Biol. (Paris). 2002;50:599-607.
21. Shifow AA, Naidu MU, Kumar KV, et al. Effect of pentoxifylline on cyclosporine-induced nephrotoxicity in rats. Indian J Exp Biol. 2000;38:347-352.
22. Boldt J, Muller M, Heesen M, et al. The effects of pentoxifylline on circulating adhesion molecules in critically ill patients with ARF treated by CVVH. Intensive Care Med. 1996;22:305-311.
23. Boldt J, Brosch C, Piper SN, et al. Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients. Crit Care Med. 2001;29:952-958.
24. Dousa TP. Cyclic-3′, 5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int. 1999;55:29-62.
25. Dousa TP. Signaling role of PDE isozymes in pathobiology of glomerular mesangial cells. Studies in vitro and in vivo. Cell Biochem. Biophys. 1998;29:19-34.
26. Dumaz N, Marais R. Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. J. Biol. Chem. 2003;278(29):819-823.
27. Chini CS, Chini EN, Williams JM, Matousovic K, Dousa TP. Formation of reactive oxygen metabolites in glomeruli is suppressed by inhibition of cAMP phosphodiesterase isozyme type IV. Kidney Int. 1994;46:28-36.
28. Tsuboi Y, Shankland SJ, Grande JP, Walker HJ, Johnson RJ, Dousa TP. Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV. J. Clin. Invest. 1996;98:262-270.
29. Seldon PM, Barnes PJ, Meja K, Giembycz MA. Suppression of lipopolysaccharide-induced tumour necrosis factor-a generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: Interaction with stimulants of adenylyl cyclase. Mol. Pharmacol. 1995;48:747-757.
30. Klahr S, Morrissey J. Progression of chronic renal disease. Am. J. Kidney Dis. 2003;41:S3-S7.
31. Heystek HC, Thierry AC, Soulard P, Moulon C. Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. Int. Immunol. 2003;15:827-835.
32. Shimizu E, Kobayashi Y, Oki Y, Kawasaki T, Yoshimi T, Nakamura H. OPC-13013, a cyclic nucleotide phosphodiesterase type III inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells. Life. Sci. 1999;64:2081-2088.
33. Kohyama T, Liu X, Wen FQ, et al. PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am. J. Respir. Cell. Mol. Biol. 2002;26:694-701.
34. Meskini N, Nemoz G, Okyayuz-Baklouti I, Lagarde M, Prigent AF. Phosphodiesterase inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculation. Biochem. Pharmacol. 1994;47:781-788.
35. Schermuly RT, Roehl A, Weissmann N, et al. Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001;281:L1361-L1368.
36. Ward A, Clissold SI. Pentoxifylline: A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy. Drugs. 1987;34:50-97.
37. Lin SL, Chen YM, Chien CT, Chiang WC, Tsai CC, Tsai TJ. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J. Am. Soc. Nephrol. 2002;13:2916-2929.
38. Tsai TJ, Lin RH, Chang CC, et al. Vasodilator agents modulate rat glomerular mesangial cell growth and collagen synthesis. Nephron. 1995;70:91-100.
39. Albornoz LE, Sanchez SB, Bandi JC, Canteros G, de las Heras M, Mastai RC. Pentoxifylline reduces nephrotoxicity associated with cyclosporine in the rat by its rheological properties. Transplant. 1997;64:1404-1407.
40. Chen YM, Chien CT, Hu-Tsai MI, et al. Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int. 1999;56:932-943.
41. Lin SL, Chen RH, Chen YM, Chiang WC, Tsai TJ, Hsieh BS. Pentoxifylline inhibits platelet-derived growth factor-stimulated cyclin D1 expression in mesangial cells by blocking Akt membrane translocation. Mol. Pharmacol. 2003;64:811-822.
42. Chen YM, Chiang WC, Lin SL, Wu KD, Tsai TJ, Hsieh BS. Dual regulation of TNF-a-induced CCL2/monocyte chemoattractant protein-1 expression in vascular smooth muscle sells by NF-kB and AP-1: Modulation by type III phosphodiesterase inhibition. J. Pharmacol. Exp. Ther. 2004;309:978-986.
43. Chen YM, Ng YY, Lin SL, Chiang WC, Lan HY, Tsai TJ. Pentoxifylline suppresses renal tumour necrosis factor-a and ameliorates experimental crescentic glomerulonephritis in rats. Nephrol. Dial. Transplant. 2004;19:1106-1115.
44. Navarro JF, Mora C, Rivero A, et al. Urinary protein excretion and serum tumour necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administration. Am. J. Kidney. Dis. 1999;33:458-463.
45. Navarro JF, Mora C, Muros M, Maca M, Garca J. Effects of pentoxifylline administration on urinary N-acetyl-b-glucosaminidase excretion in type 2 diabetic patients: A short-term, prospective randomized study. Am. J. Kidney Dis. 2003;42:264-270.
46. Ducloux D, Bresson-Vautrin C, Chalopin JM. Use of pentoxifylline in membranous nephropathy. Lancet. 2001;357:1672-1673.
47. Segal R, Dayan M, Zinger H, Mozes E. Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNF-a monoclonal antibody and by pentoxifylline. Lupus. 2001;10:23-31.